Press Releases

July 26, 2011 | Press Release
  The text of Chairman Upton's remarks in support of H.R. 1938 , the North American-Made Energy Security Act, follows below:
July 22, 2011 | Press Release
WASHINGTON, DC - The Obama administration's Office of Management and Budget has failed to comply with the House Energy and Commerce Committee's subpoena seeking documents relating to the Department of Energy's issuance of a loan guarantee to Solyndra, Inc. OMB is responsible for reviewing and approving the Credit Subsidy Costs of all DOE loan guarantees.
July 22, 2011 | Press Release
WASHINGTON, D.C. - U.S. Senator Carl Levin (D-MI), House Energy and Commerce Chairman Fred Upton (R-MI06), and U.S. Congressman John D. Dingell (D-MI15) were joined by Michigan Delegation colleagues yesterday in sending a letter to President Obama regarding the importance of one national program for vehicle emissions.  Below is the text of the letter: Dear Mr. President:
July 21, 2011 | Press Release
WASHINGTON, DC - Energy and Commerce Committee Chairman Fred Upton (R-MI) and Environment and the Economy Subcommittee Chairman John Shimkus (R-IL) today called on Nuclear Regulatory Commission Chairman Gregory Jaczko to release the full and uncensored safety evaluation for the Yucca Mountain nuclear repository. 
July 21, 2011 | Press Release
WASHINGTON, DC - U.S. House Energy and Commerce Committee Chairman Fred Upton (R-MI) today praised introduction of the Senate's EPA Regulatory Relief Act, a bipartisan Senate proposal that shares many features of a bill introduced last month in the House to protect hundreds of thousands of jobs. Reps. Morgan Griffith (R-VA) and G.K.
July 20, 2011 | Press Release
WASHINGTON, DC - The House Energy and Commerce Subcommittee on Oversight and Investigations, chaired by Rep. Cliff Stearns (R-FL), today held a hearing on the Food and Drug Administration's medical device regulations and the impact on American patients, innovation, and job creation. Patients and innovators adversely affected by regulatory inconsistencies and inefficiencies at the FDA shared their personal testimonies and Dr.

Pages